Skip to main content

Eikon Therapeutics, Inc.

EIKN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001861123

In the last 90 days, Eikon Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 77 institutions reported holding it in 13F filings for Q2 2026, worth $344.1M in total; no superinvestor holds it.

Superinvestors holding EIKN, Q2 2026

See all superinvestors

No superinvestor reported holding EIKN in Q2 2026.